Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases
- PMID: 29691844
- PMCID: PMC7988484
- DOI: 10.1002/bjs.10838
Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases
Abstract
Background: This study sought to develop a clinical risk score for resectable colorectal liver metastasis (CRLM) by combining clinicopathological and clinically available biological indicators, including KRAS.
Methods: A cohort of patients who underwent resection for CRLM at the Johns Hopkins Hospital (JHH) was analysed to identify independent predictors of overall survival (OS) that can be assessed before operation; these factors were combined into the Genetic And Morphological Evaluation (GAME) score. The score was compared with the current standard (Fong score) and validated in an external cohort of patients from the Memorial Sloan Kettering Cancer Center (MSKCC).
Results: Six preoperative predictors of worse OS were identified on multivariable Cox regression analysis in the JHH cohort (502 patients). The GAME score was calculated by allocating points to each patient according to the presence of these predictive factors: KRAS-mutated tumours (1 point); carcinoembryonic antigen level 20 ng/ml or more (1 point), primary tumour lymph node metastasis (1 point); Tumour Burden Score between 3 and 8 (1 point) or 9 and over (2 points); and extrahepatic disease (2 points). The high-risk group in the JHH cohort (GAME score at least 4 points) had a 5-year OS rate of 11 per cent, compared with 73·4 per cent for those in the low-risk group (score 0-1 point). Importantly, in cohorts from both the JHH and MSKCC (747 patients), the discriminatory capacity of the GAME score was superior to that of the Fong score, as demonstrated by the C-index and the Akaike information criterion.
Conclusion: The GAME score is a preoperative prognostic tool that can be used to inform treatment selection.
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.
Conflict of interest statement
Figures



Similar articles
-
Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis.Surgery. 2020 Sep;168(3):497-503. doi: 10.1016/j.surg.2020.05.019. Epub 2020 Jul 13. Surgery. 2020. PMID: 32675031
-
Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.J Am Coll Surg. 2021 Apr;232(4):590-598. doi: 10.1016/j.jamcollsurg.2020.11.023. Epub 2020 Dec 28. J Am Coll Surg. 2021. PMID: 33383214
-
Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.Cancer. 2016 Sep 1;122(17):2698-707. doi: 10.1002/cncr.30085. Epub 2016 May 31. Cancer. 2016. PMID: 27244540
-
Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making.Eur J Surg Oncol. 2017 May;43(5):875-883. doi: 10.1016/j.ejso.2017.02.014. Epub 2017 Mar 6. Eur J Surg Oncol. 2017. PMID: 28302330 Review.
-
Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases.Chin Clin Oncol. 2019 Oct;8(5):47. doi: 10.21037/cco.2019.08.07. Epub 2019 Sep 3. Chin Clin Oncol. 2019. PMID: 31500425 Review.
Cited by
-
Association of various RAS codon mutations and prognostic outcomes of patients with colorectal liver metastases after hepatectomy.Cancer Med. 2024 Oct;13(19):e70168. doi: 10.1002/cam4.70168. Cancer Med. 2024. PMID: 39377605 Free PMC article.
-
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study.Cancers (Basel). 2022 Nov 9;14(22):5513. doi: 10.3390/cancers14225513. Cancers (Basel). 2022. PMID: 36428606 Free PMC article.
-
Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy.Therap Adv Gastroenterol. 2021 Dec 19;14:17562848211066206. doi: 10.1177/17562848211066206. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34987612 Free PMC article.
-
Outcome prediction after resection of colorectal cancer liver metastases: out with the old, in with the new?Hepatobiliary Surg Nutr. 2024 Aug 1;13(4):732-735. doi: 10.21037/hbsn-24-187. Epub 2024 Jul 23. Hepatobiliary Surg Nutr. 2024. PMID: 39175724 Free PMC article. No abstract available.
-
Challenges and Opportunities for Precision Surgery for Colorectal Liver Metastases.Cancers (Basel). 2024 Jun 28;16(13):2379. doi: 10.3390/cancers16132379. Cancers (Basel). 2024. PMID: 39001441 Free PMC article. Review.
References
-
- Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM. Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg. 1997;132:505–510; discussion 511. - PubMed
-
- Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010;210:755–764, 764–756. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous